Vol 92, No 2 (2021)
Guidelines / Expert consensus
Published online: 2021-02-26
Cervical cancer screening in Poland in current SARS-CoV-2 pandemic: Interim guidelines of the Polish Society of Gynecologists and Obstetricians and the Polish Society of Colposcopy and Cervical Pathophysiology — a summary January 2021
DOI: 10.5603/GP.2021.0043
Ginekol Pol 2021;92(2):165-173.
Abstract
The Polish Society of Colposcopy and Cervical Pathophysiology (PTKiPSM) together with the Polish Society of Gynecologists and Obstetricians (PTGiP) issued a final summary of interim guidelines for secondary cervical cancer prevention during the SARS-CoV-2 pandemic based on the analysis of the latest directional publications and the authors’ own experiences. The aim of the summary is to facilitate the implementation of the most effective possible screening of cervical precancerous lesions and cervical cancer due to temporary significant limitation of screening as a consequence of the ongoing epidemiological threat. These final guidelines are taking into account the 2020 call of the World Health Organization (WHO) for global epidemiological elimination of cervical cancer. The guidelines supplement the interim guidelines of PTKiPSM and PTGiP announced in March 2020 on the possible deferral of diagnostic and therapeutic procedures in patients with abnormal screening tests results in secondary prevention of cervical cancer in current pandemic.
Keywords: cervical cancer preventionabnormal screening resultsHPV testingcervical cytologyselfsamplingSARS-CoV-2 pandemicguidelines
References
- WHO Call. Global Strategy Towards the Elimination of Cervical Cancer as a Public Health Problem. Geneva, Switzerland: WHO; 2019. https://www.who.int/docs/default-source/documents/cervical-cancer-elimination- draft-strategy.pdf (05.06.2020).
- Draft Global Strategy towards eliminating cervical cancer as a public health problem. WHO 5 April 2020/Publication. https://www.who.int/publications/m/item/draft-global-strategy-towards-eliminating-cervical-cancer-as-a-public-health-problem (05.06.2020).
- Gultekin M, Ramirez PT, Broutet N, et al. World Health Organization call for action to eliminate cervical cancer globally. Int J Gynecol Cancer. 2020; 30(4): 426–427.
- Arbyn M, Gultekin M, Morice P, et al. The European response to the WHO call to eliminate cervical cancer as a public health problem. Int J Cancer. 2021; 148(2): 277–284.
- Jach R, Mazurec M, Nowakowski A, Pityński K. KOLPOSKOPIA 2020: POLSKA NOMENKLATURA KOLPOSKOPOWA w oparciu o mianownictwo IFCPC 2011. Podsumowanie Konsensusu Ekspertów. Rekomendacje Grupy Ekspertów Polskiego Towarzystwa Ginekologów i Położników oraz Polskiego Towarzystwa Kolposkopii i Patofizjologii Szyjki Macicy. https://www.ptgin.pl/sites/default/files/page-2020/NOMENKLATURA%20KOLPOSKOPOWA%20strona%20www%20.pdf (03.10.2020).
- Jach R, Mazurec M, Trzeszcz M, et al. COLPOSCOPY 2020 - COLPOSCOPY PROTOCOLS: A Summary of the Clinical Experts Consensus Guidelines of the Polish Society of Colposcopy and Cervical Pathophysiology and the Polish Society of Gynaecologists and Obstetricians. Ginekol Pol. 2020; 91(6): 362371.
- Mast Ch, del Rio AM. Data Analysis | Update Delayed Cancer Screenings—A Second Look Abstract: Mid-June volumes of preventive breast, colon, and cervical cancer screenings remain 29%-36% lower than their pre-COVID-19 levels. Epic Health Research Network. July 17, 2020. https://ehrn.org/articles/delayed-cancer-screenings-a-second-look (03.10.2020).
- NFZ. Dane o realizacji programów/Programy profilaktyczne. Według stanu na dzień 1 stycznia 2021 r. http://www.nfz.gov.pl/dla-pacjenta/programy-profilaktyczne/dane-o-realizacji-programow/ (06.01.2021).
- Jach R, Mazurec M, Trzeszcz M, et al. Possible deferral of diagnostic and therapeutic procedures for patients with abnormal screening tests results in cervical cancer secondary prevention in current SARS-CoV-2 pandemic Interim guidelines of the Polish Society of Gynecologists and Obstetricians and the Polish Society of Colposcopy and Cervical Pathophysiology. Ginekol Pol. 2020; 91(7): 428–431.
- Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines Committee. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis. 2020; 24(2): 102–131.
- SUMMARY OF SAFETY AND EFFECTIVENESS DATA (SSED) CINTec PLUS Cytology. Premarket Approval Application (PMA) Number: P190024. Date of FDA Notice of Approval: March 10, 2020. https://www.accessdata.fda.gov/cdrh_docs/pdf19/P190024B.pdf (05.06.2020).
- FDA Executive Summary: New Approaches in the Evaluation for High-Risk Human Papillomavirus Nucleic Acid Detection Devices. https://www.fda.gov/media/122799/download (10.10.2020).
- Arbyn M, Snijders PJF, Meijer CJ, et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Microbiol Infect. 2015; 21(9): 817–826.
- Arbyn M, Hillermanns P. HPV assays validated for primary cervical cancer screening. https://www.hpvworld.com/articles/hpv-assays-validated-for-primary-cervical-cancer-screening/ (10.10.2020).
- Egemen D, Cheung LiC, Chen X, et al. Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis. 2020; 24(2): 132–143.
- Demarco M, Egemen D, Raine-Bennett TR, et al. A Study of Partial Human Papillomavirus Genotyping in Support of the 2019 ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis. 2020; 24(2): 144–147.
- Bonde JH, Sandri MT, Gary DS, et al. Clinical Utility of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Systematic Review. J Low Genit Tract Dis. 2020; 24(1): 1–13.
- Bonde J, Bottari F, Parvu V, et al. Bayesian analysis of baseline risk of CIN2 and ≥CIN3 by HPV genotype in a European referral cohort. Int J Cancer. 2019; 145(4): 1033–1041.
- Cuschieri K, Ronco G, Lorincz A, et al. Eurogin roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programs. Int J Cancer. 2018; 143(4): 735–745.
- Ajenifuja KO, Belinson J, Goldstein A, et al. Designing low-cost, accurate cervical screening strategies that take into account COVID-19: a role for self-sampled HPV typing2. Infect Agent Cancer. 2020; 15: 61.
- Hawkes D, Keung MHT, Huang Y, et al. Self-Collection for Cervical Screening Programs: From Research to Reality. Cancers (Basel). 2020; 12(4).
- Arbyn M, Smith SB, Temin S, et al. Collaboration on Self-Sampling and HPV Testing. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ. 2018; 363: k4823.
- Nasierowska-Guttmejer A, Kędzia W, Wojtylak S, et al. Polish recommendations regarding diagnostics and treatment of cervical squamous intraepithelial lesions according to the CAP/ASCCP guidelines. Ginekol Pol. 2016; 87(9): 670–676.
- Józefiak A, Kędzia W, Kotarski J, et al. Guidelines for application of molecular tests identyfying HR HPV DNA in the prevention of cervical cancer. Statement of experts from PGS (PTG) and NCLD (KIDL). Ginekol Pol. 2013; 84: 395–399.
- National Cervical Cancer Screening Programme in Poland Coordinating Centre, Polish Gynaecological Society, Polish Society of Pathologists, Polish Society of Colposcopy and Uterine Cervix Pathology. Management of abnormal pap smear--consensus guidelines of the National Cervical Cancer Screening Programme in Poland Coordinating Centre, the Polish Gynaecological Society, the Polish Society of Pathologists, and Polish Society of Colposcopy and Uterine Cervix Pathology. Ginekol Pol. 2009; 80(2): 129–138.
